MFFIA
GSK icon

McIntyre, Freedman & Flynn Investment Advisers’s GSK GSK Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-39,272
Closed -$1.4M – 63
2023
Q1 		$1.4M Sell
39,272
-4,000
-9% -$140K 1.19% 34
2022
Q4 		$1.52M Buy
+43,272
New +$1.44M 1.26% 33

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's GSK Position: Q2 2023 in Review

McIntyre, Freedman & Flynn Investment Advisers sold out of GSK (GSK) in Q2 2023, closing a stake of 39,272 shares — an estimated $1.4M sold.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in GSK in Q4 2022 and held it in 2 quarters. The position peaked at $1.52M in Q4 2022. 828 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

  • McIntyre, Freedman & Flynn Investment Advisers reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
  • McIntyre, Freedman & Flynn Investment Advisers sold 39,272 GSK shares in Q2 2023, an estimated $1.4M.
  • McIntyre, Freedman & Flynn Investment Advisers first reported a position in GSK in Q4 2022 and held it in 2 quarters.
  • McIntyre, Freedman & Flynn Investment Advisers's GSK position peaked at $1.52M in Q4 2022.
  • 828 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.